1. Home
  2. ICD-10-PCS MS-DRG V43.0
  3. Procedure Codes in MS-DRG 837 - Chemotherapy With Acute Leukemia As Secondary Diagnosis Or With High Dose Chemotherapy Agent With MCC

Procedure Codes in MS-DRG 837 - Chemotherapy With Acute Leukemia As Secondary Diagnosis Or With High Dose Chemotherapy Agent With MCC

The Medicare Severity Diagnosis-Related Group (MS-DRG) is a patient classification system used to categorize hospital cases based on clinical similarity and expected resource use. MS-DRGs organize all possible principal diagnoses into mutually exclusive groups known as Major Diagnostic Categories (MDCs), which help determine reimbursement under the Medicare Inpatient Prospective Payment System.

This section lists the procedure codes included in MS-DRG V43.0: Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC from October 1, 2025, through September 30, 2026.

MS-DRG: 837

MS-DRG Title: Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC

MCD: 17

Relative Weight: 4.8043 Relative Weight
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Geometric LOS: 4.80 Geometric Length of Stay
The geometric mean length of stay (GMLOS) is used by Medicare to calculate the reimbursement for patients whose medical treatment takes a much longer or shorter time than average.

Arithmetic LOS: 10.20 Arithmetic Length of Stay
The average length of stay (ALOS) reflects the average number of days a patient spends in a hospital for each admission.

  • 3E0 - Administration, Physiological Systems and Anatomical Regions, Introduction

    • 3E03002 - Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach

    • 3E03302 - Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach

    • 3E04002 - Introduction of High-dose Interleukin-2 into Central Vein, Open Approach

    • 3E04302 - Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach

    • 3E05002 - Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach

    • 3E05302 - Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach

    • 3E06002 - Introduction of High-dose Interleukin-2 into Central Artery, Open Approach

    • 3E06302 - Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach

    • 3E0R302 - Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach

    • 3E0S302 - Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach